Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB623 in chronic motor deficit from ischemic stroke
NCT02448641Phase 2Completed
- Sponsor
- SanBio
- Start
- Mar 2016
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of vandefitemcel in ischemic stroke, sponsored by SanBio. Started Mar 2016; status: completed.
02
Drugs
vandefitemcel
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02448641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448641.